Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Han, Ki-Hoon | - |
dc.contributor.author | Chung, Woo-Baek | - |
dc.contributor.author | Her, Sung-Ho | - |
dc.contributor.author | Park, Tae-Ho | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Choi, So-Yeon | - |
dc.contributor.author | Jung, Kyung-Tae | - |
dc.contributor.author | Park, Jong-Seon | - |
dc.contributor.author | Kim, Pum-Joon | - |
dc.contributor.author | Lee, Jong-Min | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Gwon, Hyeon-Cheol | - |
dc.contributor.author | Han, Kyoo-Rok | - |
dc.contributor.author | Chae, Jei-Keon | - |
dc.contributor.author | Kim, Woo-Shik | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Hong, Bum-Kee | - |
dc.contributor.author | Choi, Si-Wan | - |
dc.contributor.author | Chung, Namsik | - |
dc.date.accessioned | 2021-08-30T13:49:02Z | - |
dc.date.available | 2021-08-30T13:49:02Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53017 | - |
dc.description.abstract | Purpose: Although the role of high-intensity lipid lowering therapy in cardiovascular protection has broadened, concerns still exist about new-onset diabetes mellitus (NODM), especially in vulnerable patients. This study aimed to compare the effect high-dose (4 mg/d) and usual dose (2 mg/d) pitavastatin on glucose metabolism in patients with hyperlipidemia and impaired fasting glucose (IFG). Methods: In this 12-month study, glucose tolerance and lipid-lowering efficacy of high-dose pitavastatin (4 mg [study group]) was compared with that of usual dose pitavastatin (2 mg [control group]) in patients with hyperlipidemia and IFG. The primary end point was the change of glycosylated hemoglobin (HbA(1c)) after 24 weeks of treatment. The secondary end points were as follows: (1) NODM within 1 year after treatment, (2) change of lipid parameters, (3) changes of adiponectin, and (4) change of blood glucose and insulin levels. Findings: Of the total 417 patients screened, 313 patients with hypercholesterolemia and IFG were randomly assigned into groups. The mean (SD) change in HbA(1c) was 0.06% (0.20%) in the study group and 0.03% (0.22%) in the control group (P = 0.27). Within 1 year, 27 patients (12.3%) developed NODM, including 12 (10.6%) of 113 patients in the study group and 15 (14.2%) of 106 in the control group (P = 0.43). The study group had a significantly higher reduction of total cholesterol and LDL-C levels and a higher increase in apolipoprotein A1/apolipoprotein B ratio (0.68 [0.40] vs 0.51 [0.35], P < 0.01). (C) 2020 Pub-lished by Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject | STATIN THERAPY | - |
dc.subject | DIABETES-MELLITUS | - |
dc.subject | CARDIOVASCULAR EVENTS | - |
dc.subject | DOSE PITAVASTATIN | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | RISK | - |
dc.subject | METAANALYSIS | - |
dc.subject | INTERVENTION | - |
dc.subject | PREVENTION | - |
dc.title | Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1016/j.clinthera.2020.07.013 | - |
dc.identifier.scopusid | 2-s2.0-85090719093 | - |
dc.identifier.wosid | 000596677000017 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.42, no.10, pp.2036 - 2048 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 42 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 2036 | - |
dc.citation.endPage | 2048 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordPlus | CARDIOVASCULAR EVENTS | - |
dc.subject.keywordPlus | DOSE PITAVASTATIN | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordAuthor | hyperlipidemia | - |
dc.subject.keywordAuthor | impaired fasting glucose | - |
dc.subject.keywordAuthor | new-onset diabetes mellitus | - |
dc.subject.keywordAuthor | pitavastatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.